ArticleFrontiers in behavioral neuroscience2011
Relaxin-3-deficient mice showed slight alteration in anxiety-related behavior.
Article in Frontiers in behavioral neuroscience, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 56 citations in OpenAlex.
- Novel RXFP3 negative allosteric modulator RLX-33 reduces alcohol self-administration in rats.Journal of neurochemistry · 2023Article
- Postnatal development of the relaxin-3 innervation of the rat medial septum.Frontiers in neuroscience · 2023Article
- Anxiety and Depression: What Do We Know of Neuropeptides?Behavioral sciences (Basel, Switzerland) · 2022Review
- Investigation of Relaxin-3 Serum Levels in terms of Social Interaction, Communication, and Appetite as a Biomarker in Children with Autism.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2022Article
- High-Throughput Screening Campaign Identified a Potential Small Molecule RXFP3/4 Agonist.Molecules (Basel, Switzerland) · 2021Article
- Relaxin-3 Innervation From the Nucleus Incertus to the Parahippocampal Cortex of the Rat.Frontiers in neuroanatomy · 2021Article
- Molecular Mechanisms of Epileptic Encephalopathy Caused by KCNMA1 Loss-of-Function Mutations.Frontiers in pharmacology · 2021Article
- Targeted viral vector transduction of relaxin-3 neurons in the ratIBRO reports · 2020Article
- Comprehensive behavioral analysis of heterozygous Syngap1 knockout mice.Neuropsychopharmacology reports · 2019Article
- Septal GABA and Glutamate Neurons Express RXFP3 mRNA and Depletion of Septal RXFP3 Impaired Spatial Search Strategy and Long-Term Reference Memory in Adult Mice.Frontiers in neuroanatomy · 2019Article
- Distinct but overlapping binding sites of agonist and antagonist at the relaxin family peptide 3 (RXFP3) receptor.The Journal of biological chemistry · 2018Article
- Modulation of forebrain function by nucleus incertus and relaxin-3/RXFP3 signaling.CNS neuroscience & therapeutics · 2018Review
- Juvenile stress induces behavioral change and affects perineuronal net formation in juvenile mice.BMC neuroscience · 2018Article
- Comprehensive behavioral analysis of tryptophan 2,3-dioxygenase (Tdo2) knockout mice.Neuropsychopharmacology reports · 2018Article
- Ethanol Preference and Drinking Behavior Are Controlled by RNA Editing in the Nucleus Accumbens.Frontiers in behavioral neuroscience · 2018Article
- Sex-specific effects of relaxin-3 on food intake and body weight gain.British journal of pharmacology · 2017Review
- Distribution, physiology and pharmacology of relaxin-3/RXFP3 systems in brain.British journal of pharmacology · 2017Review
- Relaxin' the brain: a case for targeting the nucleus incertus network and relaxin-3/RXFP3 system in neuropsychiatric disorders.British journal of pharmacology · 2017Review
- Altered relaxin family receptors RXFP1 and RXFP3 in the neocortex of depressed Alzheimer's disease patients.Psychopharmacology · 2016Article
- Comparative Distribution of Relaxin-3 Inputs and Calcium-Binding Protein-Positive Neurons in Rat Amygdala.Frontiers in neuroanatomy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Relaxin-3 is a neuropeptide belonging to the relaxin/insulin superfamily. Studies using rodents have revealed that relaxin-3 is predominantly expressed in neurons in the nucleus incertus (NI) of the pons, the axons of which project to forebrain regions including the hypothalamus. There is evidence that relaxin-3 is involved in several functions, including food intake and stress responses. In the present study, we generated relaxin-3 gene knockout (KO) mice and examined them using a range of behavioral tests of sensory/motor functions and emotion-related behaviors. The results revealed that relaxin-3 KO mice exhibited normal growth and appearance, and were generally indistinguishable from wild genotype littermates. There was no difference in bodyweight among genotypes until at least 28 weeks after birth. In addition, there were no significant differences between wild-type and KO mice in locomotor activity, social interaction, hot plate test performance, fear conditioning, depression-like behavior, and Y-maze test performance. However, in the elevated plus maze test, KO mice exhibited a robust increase in the tendency to enter open arms, although they exhibited normal performance in a light/dark transition test and showed no difference from wild-type mice in the time spent in central area in the open field test. On the other hand, a significant increase in the acoustic startle response was observed in KO mice. These results indicate that relaxin-3 is slightly involved in the anxiety-related behavior.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.